Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29010966 | 0.98 | CYP1A2 (0.68) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| Bromide SCHEMBL17895414 | 0.98 | CYP1A2 (0.68) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL31374393 | 0.93 | CYP1A2 (0.61) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL1816233 | 0.86 | CYP1A2 (0.71) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL13879960 | 0.84 | CYP1A2 (0.69) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL13098582 | 0.84 | CYP1A2 (0.69) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL1536431 | 0.84 | CYP1A2 (0.69) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL13151287 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL24248340 | 0.83 | SMN1; SMN2 (0.72) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A | |
| SCHEMBL4871149 | 0.83 | CYP1A2 (0.76) | CYP1A2CYP2C19SMN1; SMN2GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| EP-3954685-B1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | US HEALTH (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240368087-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-11-07 | — | — | US | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-02-13 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| CN-109996797-B | 1H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | 美国政府健康及人类服务部 | 2022-07-22 | — | — | CN | disclosed |
| WO-2016109559-A2 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109559-A2 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-07-07 | — | — | WO | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| EP-2137158-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | MethylGene Inc. (CA) | 2009-12-30 | — | — | EP | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008104077-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | METHYLGENE INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | CYP1A2 1465/4885CYP2C19 2254/4885SMN1; SMN2 2461/4885 |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885 |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885 |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | LDHA, LDHB, XDH | CYP1A2 864/4885CYP2C19 799/4885SMN1; SMN2 3180/4885 |
| US-20240368087-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | LDHB, LDHA, PDHA1 | CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | CYP1A2 1743/4885CYP2C19 668/4885SMN1; SMN2 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.